Results 211 to 220 of about 38,934 (294)

Association of cerebrovascular disease with adverse outcomes in patients with diabetic ketoacidosis. [PDF]

Endocr Connect
Zhu X, Jin J, Hu X, Zhang P, Huo Z, Yu H, Liang W, Guan H, Li H.   +8 more
europepmc   +1 more source

Knowledge, attitude, and practice of physicians toward the management of diabetic ketoacidosis. [PDF]

Front Clin Diabetes Healthc
Al-Rasheedi M, Ibrahim B, Haider KH, Ali AA, Zainal H.   +4 more
europepmc   +1 more source

Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review. [PDF]

Front Endocrinol (Lausanne)
Jiang Y, Cui Y, Su D, Yang H, Chen X, Qian X, Tang L, Xu S.   +7 more
europepmc   +1 more source

The Risk of Disease Progression of Type 1 Diabetes in First‐Degree Relatives of People With Type 1 Diabetes: Design and Rationale of a Prospective, Longitudinal Study in China

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4610-4618, June 2026.
ABSTRACT Aims In China, information on individuals who test positive for islet autoantibodies (IAb), including single IAb‐positive individuals and those with early‐stage Type 1 diabetes (T1D), and their risk of progression to Stage 3 T1D is limited. The goal of this study is to assess the risk of progression to T1D in first‐degree relatives (FDRs) of ...
Lixin Guo, Xiaoping Luo, Yan Bi, Bingyan Cao, Guanping Dong, Sheng Jiang, Guijun Qin, Hong Qiao, Zhongyan Shan, Tao Yang, Gaohui Zhu, Min Li, Sunyinyan Tang, Minlu Zhang, Wenjuan Li   +14 more
wiley   +1 more source

Metabolic Acidosis in Chronic Alcoholism: When It's Not Just Diabetic Ketoacidosis. [PDF]

Cureus
Li R, Han J, Sidhu H.
europepmc   +1 more source

Efficacy and Safety of Automated Insulin Delivery in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5091-5100, June 2026.
ABSTRACT Aims Studies evaluating automated insulin delivery (AID) in type 2 diabetes are limited in number and often conducted in small cohorts. We aimed to summarize efficacy and safety data through a systematic review and meta‐analysis. Materials and Methods We searched MEDLINE, PubMed, Web of Science, and CENTRAL databases and performed hand ...
Sergio Di Molfetta, Ludovico Di Gioia, Irene Caruso, Mariangela Caporusso, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino   +7 more
wiley   +1 more source

Diabetic ketoacidosis in patients with type 2 diabetes: Risk factors for mortality and adverse outcomes. [PDF]

World J Exp Med
Chandrabalan V, Howcroft T, Alkhalifah MK, Younis N, Aldhafiri E, Pappachan JM.   +5 more
europepmc   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Interrelationship Between Baseline HbA1c, SGLT‐2 Inhibitor Use and Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.
ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu, Setor K. Kunutsor, Erwin Taguiam, Kamlesh Khunti   +3 more
wiley   +1 more source